|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1968, Vol. 32, No. 3, pp. 436-444.
© 1968 American Society of Hematology, Inc.
Immunosuppression by Cyclophosphamide in NZB X
NZW Mice With Lupus Nephritis
T. P. CASEY 1
1 Department of Pathology, University of Otago Medical School, Dunedin,
New Zealand.
Long-term administration of cyclophosphamide to groups of young and old
NZB X NZW hybrid mice in controlled therapeutic trials showed:
1. decreased antinuclear autoantibody production as judged by LE cell and
latex nucleoprotein tests,
2. marked benefit to lupus nephritis lesions, and
3. no carcinogenic effects.
Attention is drawn to the prospect of using these mice to study the carcinogenic effects of antimitotic drugs with particular reference to the effects
of such drugs on immune mechanisms.
Submitted on December 19, 1967
Accepted on March 19, 1968
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Frese-Schaper, J. Zbaeren, M. Gugger, M. Monestier, and S. Frese
Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black x New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan
J. Immunol.,
February 15, 2010;
184(4):
2175 - 2182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Venegas-Pont, J. C. Sartori-Valinotti, C. Maric, L. C. Racusen, P. H. Glover, G. R. McLemore Jr., A. V. Jones, J. F. Reckelhoff, and M. J. Ryan
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2009;
296(4):
R1282 - R1289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Kulkarni, D. Eulberg, N. Selve, S. Zollner, R. Allam, R. D. Pawar, S. Pfeiffer, S. Segerer, S. Klussmann, and H.-J. Anders
Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of Cyclophosphamide to Control Diffuse Proliferative Lupus Nephritis and Pneumonitis in MRL-Fas(lpr) Mice
J. Pharmacol. Exp. Ther.,
February 1, 2009;
328(2):
371 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bhattacharya, R. A. Lawrence, A. Krishnan, K. Zaman, D. Sun, and G. Fernandes
Effect of Dietary n-3 and n-6 Oils with and without Food Restriction on Activity of Antioxidant Enzymes and Lipid Peroxidation in Livers of Cyclophosphamide Treated Autoimmune-Prone NZB/W Female Mice
J. Am. Coll. Nutr.,
October 1, 2003;
22(5):
388 - 399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kinoshita, B.-S. Yoo, Y. Nozaki, M. Sugiyama, S. Ikoma, M. Ohno, M. Funauchi, and A. Kanamaru
Retinoic Acid Reduces Autoimmune Renal Injury and Increases Survival in NZB/W F1 Mice
J. Immunol.,
June 1, 2003;
170(11):
5793 - 5798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Daikh and D. Wofsy
Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide
J. Immunol.,
March 1, 2001;
166(5):
2913 - 2916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Ader and N Cohen
Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus
Science,
March 19, 1982;
215(4539):
1534 - 1536.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. F. ROTHFIELD
Immunosuppressive Therapy in Lupus Erythematosus
Ann Intern Med,
November 1, 1975;
83(5):
727 - 728.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. H. FERGUSON and J. W. WORTHINGTON
Recent Advances in Rheumatic Diseases: 1967 Through 1969
Ann Intern Med,
July 1, 1970;
73(1):
109 - 124.
[Abstract]
[PDF]
|
|
|
|
|
